SynthesisTomography (Ann Arbor, Mich.)2026
The Role of Artificial Intelligence in the Characterization and Outcome Prediction of Prostate Cancer: A Systematic Review.
Synthesis in Tomography (Ann Arbor, Mich.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesProstate cancer (PCa) is the second most commonly diagnosed cancer in men globally. Radiation oncologists often find PCa tumor characterization and outcome prediction challenging. Therefore, the potential for artificial intelligence (AI) implementation in radiation oncology has increased in recent years. This systematic review aims to evaluate the efficacy of AI algorithms in characterizing PCa tumors and predicting post-therapy outcomes.
methodsA total of 2055 studies were identified through a comprehensive search across PubMed and Scopus, then exported to Covidence. Inclusion criteria focused on prospective and retrospective cohort studies as well as randomized clinical trials (RCTs) published between 2015 and 2024 that explored the implementation of AI in tumor characterization and outcome prediction of PCa. Two independent reviewers evaluated each paper, and evaluation metrics such as specificity, sensitivity, accuracy, and area under the curve (AUC) were analyzed. The Risk of Bias in Non-randomized Studies of Interventions, Version 2 (ROBINS-I V2) tool was used to assess the risk of bias (ROB).
resultsAcross the 19 studies analyzed, there was no significant difference in model performance between machine learning (ML) and deep learning (DL) models. AI models using multi-input strategies (e.g., radiomics with clinical markers) generally performed better than single-input models. Of the imaging modalities used for radiomic feature extraction, multiparametric MRI (mpMRI)-trained AI models consistently achieved the highest performance.
conclusionsAI displays considerable potential for integration into clinical workflows for PCa management. However, further studies utilizing larger datasets and external cohorts independent of the sample population are needed to validate clinical utility and improve model transparency for reliable implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.